AQXP - Aquinox Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.59
-0.04 (-0.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.29
Open12.66
Bid12.14 x 2300
Ask13.20 x 300
Day's Range12.47 - 12.85
52 Week Range10.02 - 16.90
Volume40,212
Avg. Volume112,960
Market Cap295.767M
Beta-17.77
PE Ratio (TTM)N/A
EPS (TTM)-2.14
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.25
Trade prices are not sourced from all markets
  • ACCESSWIRE26 days ago

    Free Research Report as Zoetis’ Quarterly Revenues Gained 13% and Adjusted EPS Soared 47%

    Stock Monitor: Aquinox Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free earnings report on Zoetis Inc. (NYSE: ZTS ). If you want access ...

  • GlobeNewswirelast month

    Aquinox to Present at the 17th Annual Needham Healthcare Conference

    VANCOUVER, British Columbia, March 21, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • Associated Presslast month

    Aquinox reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 69 cents. For the year, the company reported that its loss widened to $50.2 million, or $2.14 per share. Aquinox ...

  • GlobeNewswirelast month

    Aquinox Pharmaceuticals Announces Year End 2017 Financial Results

    VANCOUVER, British Columbia, March 12, 2018--. Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • ACCESSWIRElast month

    Aquinox Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018, at 4:30 PM Eastern ...

  • Reuterslast month

    Morning News Call - Canada, March 12

    To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/morning_News_Call/MNCGeneric_CA_03122018.pdf You can read Morning News Call Canada via TOPNEWS Canada page. ...

  • GlobeNewswire2 months ago

    Aquinox Pharmaceuticals to Announce Year End 2017 Financial Results

    VANCOUVER, British Columbia, March 05, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • GlobeNewswire2 months ago

    Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor

    --Enrollment target reached; topline data on track for Q3 2018 announcement--. NEW YORK, Feb. 09, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing ...

  • Comparing Cara Therapeutics’ Financial Performance
    Market Realist3 months ago

    Comparing Cara Therapeutics’ Financial Performance

    What's in Store for Cara Therapeutics in 2018?

  • Cara Therapeutics’ Collaboration Agreements
    Market Realist3 months ago

    Cara Therapeutics’ Collaboration Agreements

    What's in Store for Cara Therapeutics in 2018?

  • GlobeNewswire3 months ago

    Aquinox to Present at LEERINK Partners 7th Annual Global Healthcare Conference

    VANCOUVER, British Columbia, Feb. 02, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • An Insight into Cara Therapeutics’ Drug Pipeline
    Market Realist3 months ago

    An Insight into Cara Therapeutics’ Drug Pipeline

    Cara Therapeutics’ (CARA) investigational drug candidate, CR845, is being developed for providing pain relief. Intravenous (or IV) CR845 has shown a pain relief and tolerability profile in three Phase 2 clinical trials in patients with acute postoperative pain. Cara Therapeutics has initiated a Phase 3 clinical trial program for IV CR845 for postoperative pain in patients undergoing a range of abdominal surgeries.

  • Analysts’ Recommendations for Cara Therapeutics in January 2018
    Market Realist3 months ago

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.

  • GlobeNewswire3 months ago

    Aquinox to Host Analyst and Investor Event in New York City

    VANCOUVER, British Columbia, Jan. 26, 2018-- Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory ...

  • Associated Press5 months ago

    Aquinox reports 3Q loss

    The Vancouver, British Columbia-based company said it had a loss of 50 cents per share. Aquinox shares have declined 34 percent since the beginning of the year. The stock has dropped almost 1 percent in ...

  • Associated Press8 months ago

    Aquinox reports 2Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 59 cents. Aquinox shares have dropped roughly 10 percent since the beginning of the year. The stock has increased ...

  • ACCESSWIRE8 months ago

    Investor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Aquinox Pharmaceuticals, Inc. (NASDAQ: AQXP ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 8:30 ...